ArticleThe EMBO journal2023
NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness.
Open access · bronzeAbstract read
In one paragraph
Article in The EMBO journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- The ubiquitin-activating enzyme inhibitor TAK-243 activates store-operated CaBiochimica et biophysica acta. Molecular cell research · 2026Article
- Targeting TRPV6/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone.Signal transduction and targeted therapy · 2025Article
- Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025Review
- Invadopodia in cancer metastasis: dynamics, regulation, and targeted therapies.Journal of translational medicine · 2025Review
- SLO2.1/NALCN Functional Complex Activity in Mouse Myometrial Smooth Muscle Cells During Pregnancy.Journal of cellular physiology · 2025Article
- Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.Nature communications · 2025Article
- Recent advances in the role of high-salt diet in anti- and pro-cancer progression.Frontiers in immunology · 2025Review
- Article
- A novel NaOncogene · 2024Article
- Causality investigation among gut microbiota, immune cells, and prostate diseases: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Pan-cancer ion transport signature reveals functional regulators of glioblastoma aggression.The EMBO journal · 2024Article
- Malignant currents: sodium leak channel NALCN propels prostate cancer aggressiveness.The EMBO journal · 2023Article
- NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness.The EMBO journal · 2023Article
Corrections and comments
- Commented on by
Authors and funding
34 authors at 11 institutions in 6 countries.
Antoine Folcher *Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.ORCID 0000-0002-4483-7019
Dmitri Gordienko *Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.ORCID 0000-0002-4118-9976
Oksana Iamshanova *Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.ORCID 0000-0002-1984-0013
Alexandre BokhobzaInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.ORCID 0000-0001-7953-4328
George ShapovalovInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
Dheeraj Kannancheri-PuthooruInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
Pascal MariotInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
Laurent AllartInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
Emilie DesruellesInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
Corentin SprietTISBio, Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), CNRS, UMR 8576, Université de Lille, Lille, France.
Raquel DiezCell Physiology Research Group, Department of Physiology, University of Extremadura, Cáceres, Spain.
Thibauld OullierCancéropôle du Grand Ouest, Plateforme In Vivo, Nantes, France.
Séverine Marionneau-LambotCancéropôle du Grand Ouest, Plateforme In Vivo, Nantes, France.
Lucie BrissonInserm UMR1069, Nutrition Croissance et Cancer, University of Tours, Tours, France.ORCID 0000-0001-7811-1382
Sandra GeraciUniv Lyon, Université Claude Bernard Lyon 1, Inserm UMR 1033 LYOS, Lyon, France.
Hathaichanok ImphengDepartment of Physiology, Faculty of Medical science, Naresuan University, Phitsanulok, Thailand.
V'yacheslav Lehen'kyiInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.ORCID 0000-0003-0806-8766
Aurélien HaustrateInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
Adriana MihalacheService d'Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l'Université Catholique de Lille, Lille, France.
Pierre GossetService d'Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l'Université Catholique de Lille, Lille, France.
Stéphanie ChadetEA4245 Transplantation, Immunology, Inflammation, University of Tours, Tours, France.ORCID 0000-0001-7383-8232
Stéphanie RetifPHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
Maryline LaubePHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
Julien SobiloPHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.ORCID 0000-0003-4284-7552
Stéphanie LerondelPHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
Giulia VillariDepartment of Oncology, University of Torino School of Medicine, Candiolo, Italy.ORCID 0000-0002-4811-3990
Guido SeriniDepartment of Oncology, University of Torino School of Medicine, Candiolo, Italy.ORCID 0000-0002-3502-8367
Alessandra Fiorio PlaDepartment of Life Science and Systems Biology, University of Torino, Torino, Italy.
Sébastien RogerEA4245 Transplantation, Immunology, Inflammation, University of Tours, Tours, France.ORCID 0000-0002-9852-5248
Gaelle Fromont-HankardInserm UMR1069, Nutrition Croissance et Cancer, University of Tours, Tours, France.
Mustafa DjamgozDepartment of Life Sciences, Imperial College London, London, UK.ORCID 0000-0003-1435-8540
Philippe ClezardinUniv Lyon, Université Claude Bernard Lyon 1, Inserm UMR 1033 LYOS, Lyon, France.
Arnaud MonteilLabEx "Ion Channel Science and Therapeutics", IGF, CNRS, INSERM, University of Montpellier, Montpellier, France.
Natalia PrevarskayaInserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.ORCID 0000-0003-0316-197X
Inserm · FRCentre National de la Recherche Scientifique · FRUniversité de Tours · FRCancéropôle Grand Ouest · FRCandiolo Cancer Institute · ITUniversité Catholique de Lille · FRUniversité Claude Bernard Lyon 1 · FRCyprus International University · CYNaresuan University · THUniversidad de Extremadura · ESUniversity of Turin · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is growing evidence that ion channels are critically involved in cancer cell invasiveness and metastasis. However, the molecular mechanisms of ion signaling promoting cancer behavior are poorly understood and the complexity of the underlying remodeling during metastasis remains to be explored. Here, using a variety of in vitro and in vivo techniques, we show that metastatic prostate cancer cells acquire a specific Na
Indexed as
Prostatic NeoplasmsSodiumHumansIon ChannelsIon TransportMaleMembrane ProteinsIon ChannelsMembrane ProteinsNALCN protein, humanSodiumcalcium oscillationsinvasiononcochannelopathySodium leak channelvesicle secretion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.